Telix Pharmaceuticals Limited Stock Performance
| TLPPF Stock | USD 16.00 0.82 5.40% |
On a scale of 0 to 100, Telix Pharmaceuticals holds a performance score of 12. The entity has a beta of -0.15, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Telix Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Telix Pharmaceuticals is likely to outperform the market. Please check Telix Pharmaceuticals' maximum drawdown, as well as the relationship between the expected short fall and day median price , to make a quick decision on whether Telix Pharmaceuticals' existing price patterns will revert.
Risk-Adjusted Performance
12 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Telix Pharmaceuticals Limited are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak basic indicators, Telix Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 77.9 M | |
| Total Cashflows From Investing Activities | -2.7 M |
Telix |
Telix Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,189 in Telix Pharmaceuticals Limited on September 16, 2024 and sell it today you would earn a total of 411.00 from holding Telix Pharmaceuticals Limited or generate 34.57% return on investment over 90 days. Telix Pharmaceuticals Limited is currently producing 0.5098% returns and takes up 3.2674% volatility of returns over 90 trading days. Put another way, 29% of traded pink sheets are less volatile than Telix, and 90% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Telix Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Telix Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Telix Pharmaceuticals Limited, and traders can use it to determine the average amount a Telix Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.156
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TLPPF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.27 actual daily | 29 71% of assets are more volatile |
Expected Return
| 0.51 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.16 actual daily | 12 88% of assets perform better |
Based on monthly moving average Telix Pharmaceuticals is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Telix Pharmaceuticals by adding it to a well-diversified portfolio.
Telix Pharmaceuticals Fundamentals Growth
Telix Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Telix Pharmaceuticals, and Telix Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Telix Pink Sheet performance.
| Return On Equity | -1.55 | |||
| Return On Asset | -0.41 | |||
| Operating Margin | (3.95) % | |||
| Current Valuation | 1.39 B | |||
| Shares Outstanding | 317.02 M | |||
| Price To Book | 21.16 X | |||
| Price To Sales | 52.21 X | |||
| Revenue | 4.9 M | |||
| EBITDA | (70.07 M) | |||
| Cash And Equivalents | 122.61 M | |||
| Cash Per Share | 0.39 X | |||
| Total Debt | 2.57 M | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 0.34 X | |||
| Cash Flow From Operations | (59.33 M) | |||
| Earnings Per Share | (0.20) X | |||
| Total Asset | 109.81 M | |||
About Telix Pharmaceuticals Performance
By analyzing Telix Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Telix Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Telix Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Telix Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company was founded in 2015 and is headquartered in North Melbourne, Australia. Telix Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Telix Pharmaceuticals performance evaluation
Checking the ongoing alerts about Telix Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Telix Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Telix Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Telix Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 4.9 M. Net Loss for the year was (80.51 M) with profit before overhead, payroll, taxes, and interest of 5.05 M. | |
| Telix Pharmaceuticals Limited has accumulated about 122.61 M in cash with (59.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39. | |
| Roughly 28.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Telix Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Telix Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Telix Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Telix Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Telix Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Telix Pharmaceuticals' pink sheet. These opinions can provide insight into Telix Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Telix Pink Sheet analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |